Based on the VanEck Genomics and Healthcare Innovators UCITS ETF GBP stock forecast from 0 analysts, the average analyst target price for VanEck Genomics and Healthcare Innovators UCITS ETF GBP is not available over the next 12 months. VanEck Genomics and Healthcare Innovators UCITS ETF GBP’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of VanEck Genomics and Healthcare Innovators UCITS ETF GBP is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, VanEck Genomics and Healthcare Innovators UCITS ETF GBP’s stock price was GBP 14.95. VanEck Genomics and Healthcare Innovators UCITS ETF GBP’s stock price has changed by -3.12% over the past week, -1.86% over the past month and 0% over the last year.
No recent analyst target price found for VanEck Genomics and Healthcare Innovators UCITS ETF GBP
No recent average analyst rating found for VanEck Genomics and Healthcare Innovators UCITS ETF GBP
Company Overview VanEck Genomics and Healthcare Innovators UCITS ETF GBP
Frequently Asked Questions About VanEck Genomics and Healthcare Innovators UCITS ETF GBP (CURG:LSE) Stock
Stock Target Advisor's fundamental analysis for VanEck Genomics and Healthcare Innovators UCITS ETF GBP's stock is Very Bearish.
Unfortunately we do not have enough data on CURG:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CURG:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CURG:LSE's stock to indicate if its overvalued.
The last closing price of CURG:LSE's stock was GBP 14.95.
The most recent market capitalization for CURG:LSE is GBP 4.80M.
Unfortunately we do not have enough analyst data on CURG:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VanEck Genomics and Healthcare Innovators UCITS ETF GBP's stock.
Sorry, we do not have any data on the number of employees for VanEck Genomics and Healthcare Innovators UCITS ETF GBP.
Sorry we do not have any infomation available on VanEck Genomics and Healthcare Innovators UCITS ETF GBP's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Frequently Asked Questions About VanEck Genomics and Healthcare Innovators UCITS ETF GBP (CURG:LSE) Stock
Stock Target Advisor's fundamental analysis for VanEck Genomics and Healthcare Innovators UCITS ETF GBP's stock is Very Bearish.
Unfortunately we do not have enough data on CURG:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CURG:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CURG:LSE's stock to indicate if its overvalued.
The last closing price of CURG:LSE's stock was GBP 14.95.
The most recent market capitalization for CURG:LSE is GBP 4.80M.
Unfortunately we do not have enough analyst data on CURG:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VanEck Genomics and Healthcare Innovators UCITS ETF GBP's stock.
Sorry, we do not have any data on the number of employees for VanEck Genomics and Healthcare Innovators UCITS ETF GBP.
Sorry we do not have any infomation available on VanEck Genomics and Healthcare Innovators UCITS ETF GBP's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CURG:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
